Skip to main content
NCD 190.28 · version 2 · Laboratory NCD

NCD 190.28: Tumor Antigen by Immunoassay - CA 125

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.28

Benefit category
Diagnostic Laboratory Tests
Effective date
01/01/2006
Implemented 01/03/2006
Transmittal
Transmittal 47
Versions published
2
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
53 covered ICD-10
233 non-covered

TL;DR

NCD 190.28 sets Medicare's national policy for tumor antigen by immunoassay - ca 125 under the benefit category "Diagnostic Laboratory Tests", effective 01/01/2006 and implemented 01/03/2006. CA 125 is a high molecular weight serum tumor marker elevated in 80% of patients who present with epithelial ovarian carcinoma. It is also elevated in carcinomas of the fallopian tube, endometrium, and endocervix. An elevated level may also be associated… As a laboratory NCD it carries a national ICD-10 edit list: 53 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.

Item or service described

Immunoassay determinations of the serum levels of certain proteins or carbohydrates serve as tumor markers. When elevated, serum concentration of these markers may reflect tumor size and grade.

This policy specifically addresses tumor antigen CA 125.

Indications and limitations of coverage

Indications

CA 125 is a high molecular weight serum tumor marker elevated in 80% of patients who present with epithelial ovarian carcinoma. It is also elevated in carcinomas of the fallopian tube, endometrium, and endocervix. An elevated level may also be associated with the presence of a malignant mesothelioma or primary peritoneal carcinoma .

A CA125 level may be obtained as part of the initial pre-operative work-up for women presenting with a suspicious pelvic mass to be used as a baseline for purposes of post-operative monitoring. Initial declines in CA 125 after initial surgery and/or chemotherapy for ovarian carcinoma are also measured by obtaining three serum levels during the first month post treatment to determine the patient's CA 125 half-life, which has significant prognostic implications.

The CA 125 levels are again obtained at the completion of chemotherapy as an index of residual disease. Surveillance CA125 measurements are generally obtained every 3 months for 2 years, every 6 months for the next 3 years, and yearly thereafter. CA 125 levels are also an important indicator of a patient's response to therapy in the presence of advanced or recurrent disease. In this setting, CA 125 levels may be obtained prior to each treatment cycle.

Limitations

These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles.

The CA 125 is specifically not covered for aiding in the differential diagnosis of patients with a pelvic mass as the sensitivity and specificity of the test is not sufficient. In general, a single "tumor marker" will suffice in following a patient with one of these malignancies.

(This NCD last reviewed November 2005)

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.28 version 2. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 53 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.28
CodeCode set
86304CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $20.81, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.28 edits, October 2026
CodeCLFS amountWith QWPricing
86304$20.81—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 53 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.28 (sample)
ICD-10-CMDescriptionEffective
C45.1Mesothelioma of peritoneum2015-10-01
C48.1Malignant neoplasm of specified parts of peritoneum2015-10-01
C48.2Malignant neoplasm of peritoneum, unspecified2015-10-01
C48.8Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum2015-10-01
C51.8Malignant neoplasm of overlapping sites of vulva2015-10-01
C53.0Malignant neoplasm of endocervix2015-10-01
C53.1Malignant neoplasm of exocervix2026-01-01
C53.8Malignant neoplasm of overlapping sites of cervix uteri2026-01-01
C53.9Malignant neoplasm of cervix uteri, unspecified2026-01-01
C54.1Malignant neoplasm of endometrium2015-10-01
C54.2Malignant neoplasm of myometrium2015-10-01
C54.3Malignant neoplasm of fundus uteri2015-10-01
C54.9Malignant neoplasm of corpus uteri, unspecified2015-10-01
C56.1Malignant neoplasm of right ovary2015-10-01
C56.2Malignant neoplasm of left ovary2015-10-01
C56.3Malignant neoplasm of bilateral ovaries2021-10-01
C56.9Malignant neoplasm of unspecified ovary2015-10-01
C57.00Malignant neoplasm of unspecified fallopian tube2015-10-01
C57.01Malignant neoplasm of right fallopian tube2015-10-01
C57.02Malignant neoplasm of left fallopian tube2015-10-01
C57.4Malignant neoplasm of uterine adnexa, unspecified2015-10-01
C57.7Malignant neoplasm of other specified female genital organs2015-10-01
C57.8Malignant neoplasm of overlapping sites of female genital organs2015-10-01
C79.60Secondary malignant neoplasm of unspecified ovary2015-10-01
C79.61Secondary malignant neoplasm of right ovary2015-10-01
C79.62Secondary malignant neoplasm of left ovary2015-10-01
C79.63Secondary malignant neoplasm of bilateral ovaries2021-10-01
C79.82Secondary malignant neoplasm of genital organs2015-10-01
D39.0Neoplasm of uncertain behavior of uterus2015-10-01
D39.10Neoplasm of uncertain behavior of unspecified ovary2015-10-01
D39.11Neoplasm of uncertain behavior of right ovary2015-10-01
D39.12Neoplasm of uncertain behavior of left ovary2015-10-01
D39.2Neoplasm of uncertain behavior of placenta2015-10-01
D39.8Neoplasm of uncertain behavior of other specified female genital organs2015-10-01
D39.9Neoplasm of uncertain behavior of female genital organ, unspecified2015-10-01
G89.3Neoplasm related pain (acute) (chronic)2015-10-01
M33.03Juvenile dermatomyositis without myopathy2017-10-01
M33.13Other dermatomyositis without myopathy2017-10-01
M33.93Dermatopolymyositis, unspecified without myopathy2017-10-01
R19.01Right upper quadrant abdominal swelling, mass and lump2021-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.28 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release made no change to this NCD's ICD-10-CM list: no code was added, removed or given a new result against January 2026. The last change was in January 2026, when CMS added 6 codes.

Codes on this NCD's list by release: October 2025: 280 · January 2026: 286 · October 2026: 286. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links one analysis to NCD 190.28, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00290R Tumor Antigen by Immunoassay CA 125 (Addition of Primary Peritoneal Adenocarcinoma as a Covered Indication) (1st Recon, Closed)

Revision history

02/2006 - Changes to the Covered Indications for Tumor Antigen by Immunoassay CA 125 to Add Primary Peritoneal Carcinoma. Effective Date: 01/01/2006. Implementation Date: 01/03/2006. ( TN 47 ) (CR 4257)

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.28

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.28

What does NCD 190.28 cover?

CA 125 is a high molecular weight serum tumor marker elevated in 80% of patients who present with epithelial ovarian carcinoma. It is also elevated in carcinomas of the fallopian tube, endometrium, and endocervix. An elevated level may also be associated with the presence of a malignant mesothelioma or primary peritoneal carcinoma . The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.28 take effect?

The current version (2) is effective 01/01/2006, implemented 01/03/2006, published in transmittal 47. CMS lists 2 versions of this NCD.

Does a Local Coverage Determination override NCD 190.28?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.28?

The October 2026 laboratory NCD edit list contains 53 ICD-10-CM codes that support tumor antigen by immunoassay - ca 125 (for example C45.1 Mesothelioma of peritoneum; C48.1 Malignant neoplasm of specified parts of peritoneum; C48.2 Malignant neoplasm of peritoneum, unspecified) and 233 codes that deny. The list applies to 86304.

How often does the lab NCD code list for 190.28 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.